Patients who fail to reach complete donor chimerism by month two after allogeneic transplant face a markedly higher relapse risk (hazard ratio 4.6, p=0.02) based on high-sensitivity assays presented at recent transplant meetings. That metric sets the bar for TScan’s near-term readouts: the company plans to share early chimerism data from Cohort C of its Phase 1 ALLOHA study in the second quarter as it readies a pivotal program for its TCR-T candidate TSC-101.
The core moves are twofold. First, TScan has completed enrollment of Cohort C in ALLOHA, with patients treated using a commercial-ready manufacturing process intended to carry forward into late-stage development. Second, FDA has cleared INDs for two CD45-targeted, HLA-restricted TCR-T products, TSC-102-A01 and TSC-102-A03, covering HLA-A•01:01 and HLA-A•03:01 populations, respectively. A Phase 1 trial for both TSC-102 constructs is slated to begin in the second half of 2026. In parallel, TScan aims to launch a pivotal trial of TSC-101 in AML and MDS in the second quarter of 2026 following Cohort C safety and early chimerism updates. ALLOHA is currently evaluating TSC-101 in HLA-A•02:01-positive patients undergoing allogeneic hematopoietic cell transplantation.
Strategically, the company is moving on three pressure points that routinely slow cell therapy programs: CMC maturity, patient addressability, and timing of efficacy signals. Locking a commercial-ready process into Phase 1 Cohort C brings comparability and tech-transfer discipline forward, potentially de-risking the hop into pivotal and reducing CMC-driven delays. Expanding HLA coverage via TSC-102 could nearly double the U.S. reach of the heme platform, countering the screen-failure problem inherent to HLA-restricted TCR-Ts. And anchoring early decision-making to donor chimerism provides a faster operational signal than relapse-free survival, even if it is not yet a validated surrogate endpoint for regulatory decisions in this setting.
For transplant centers and research sites, the program design concentrates activity at institutions already equipped for allogeneic HCT, but it adds layers that matter operationally: high-sensitivity chimerism testing by day 60, standardized HLA genotyping, and tight coordination with manufacturing slots using the new process. Screen-to-enroll efficiency will hinge on HLA distribution and central lab turnaround times. CROs and vendors should anticipate complex scheduling around reduced-intensity versus myeloablative conditioning, along with chain-of-identity rigor for multiple HLA-specific products. Regulators will be focused on whether Cohort C shows acceptable safety—particularly cytopenias, infection burden, and GVHD rates—while offering a consistent chimerism shift that can be tied prospectively to relapse risk. For sponsors in adjacent post-transplant maintenance strategies, the IND clearances around CD45 targeting signal increasing competition for the post-HCT residual disease niche.
The next catalysts are tightly sequenced. In Q2, watch for Cohort C’s safety profile under the commercial-ready process, persistence data if available, and the magnitude and timing of chimerism changes. The pivotal design for TSC-101 will reveal the company’s regulatory thesis: whether it leans on relapse-free survival as the primary endpoint with chimerism as a key secondary, or seeks an accelerated path anchored to biomarker shifts. For the new TSC-102 assets, site activation and HLA-based screening throughput will be the execution test, alongside management of on-target effects inherent to CD45-directed approaches in a post-transplant population. The open question is whether early chimerism gains can translate into durable relapse reduction without additive toxicity; that linkage will determine both regulatory posture and the operational burden centers are willing to absorb.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
